Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide

111: 2509–2517 12. Nakao A, Okumura K, Ogawa H. Smad7: a new key player in TGF-beta-associated disease. Trends Mol Med 2002; 8: 361–363 13. Li JH, Zhu HJ, Huang XR et al. Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002; 13: 1464–1472 14. Lan HY, Mu W, Tomita N et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003; 14: 1535–1548 15. Chen R, Huang C, Morinelli TA, Trojanowska M, Paul RV. Blockade of the effects of TGF-beta1 on mesangial cells by overexpression of Smad7. J Am Soc Nephrol 2002; 13: 887–893 16. Hao J, Wang B, Jones SC, Jassal DS, Dixon IM. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol 2000; 279: H3020–H3030 17. Wamsley-Davis A, Padda R, Truong LD et al. AT1A-mediated activation of kidney JNK1 and SMAD2 in obstructive uropathy: preservation of kidney tissue mass using Candesartan. Am J Physiol 2004; 287: F474–F480 18. Yamakawa T, Tanaka S, Numaguchi K et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000; 35: 313–318 19. Nagatoya K, Moriyama T, Kawada N et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 1684–1695 20. Kanda T, Wakino S, Hayashi K et al. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64: 2009–2019 21. Satoh S, Yamaguchi T, Hitomi A et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 2002; 455: 169–114 22. Teraishi K, Kurata H, Nakajima A et al. Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/ reperfusion-induced acute renal failure in rats. Eur J Pharmacol 2004; 505: 205–211 23. Nishikimi T, Akimoto K, Wang X et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. Hypertensenion 2004; 22: 1787–1796 24. Kataoka C, Egashira K, Inoue S et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39: 245–250 25. Rupérez M, Sánchez-López E, Blanco-Colio LM et al. The Rho-kinase pathway regulates AngII-induced renal damage Kidney Int 2005; 68 [Supp 99] 26. Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998; 274: F580–F586 27. Esteban V, Ruperez M, Vita JR et al. Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int 2003; 86: S33–S38 28. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factorB through AT1 and AT2 receptors. Kidney Int 2002; 61: 1986–1995 29. Rodriguez-Iturbe B, Ferrebuz A, Varegas V et al. Early and sustained inhibition of nuclear factor kappa B prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005; 315: 51–77 30. Mezzano S, Aros C, Droguett A et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505–2512 31. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799–812